Current long acting HIV therapies face challenges like prolonged pharmacokinetic tails, which increase resistance risk. The authors develop dimeric bictegravir prodrug nanosuspensions that sustain therapeutic levels for six months with a short PK tail, supporting safer ultra-long-acting HIV treatment.
- Mohammad Ullah Nayan
- Brady Sillman
- Benson Edagwa
